Genetic Signatures (GSS) H2 2025 earnings summary

Executive summary

• Revenue increased 63% year-over-year to $15.9 million, driven by strong respiratory sales in Australia and extended respiratory season.

• Underlying loss reduced by 28% to $12.7 million, while statutory loss was $20.1 million due to a $7.0 million impairment expense.

• Strategic refocus implemented, including new leadership appointments and operational streamlining.

• First US commercial contract secured, marking entry into a major new market.

• Emphasis on early infectious disease detection and combating antimicrobial resistance with proprietary PCR technology.

Financial highlights

• Gross margin improved to 55% from 53% in the prior year, with gross profit at $8.8 million.

• Cash and term deposits at $30.9 million as of June 30, 2025, with no debt.

• Net operating cash outflows of $12.3 million, including a $5.0 million R&D rebate.

• Employee expenses increased 6% due to salary adjustments and new hires.

• $5.4 million in other income from R&D tax incentives and interest income.

Outlook and guidance

• US focus: roll out revised go-to-market strategy and expect revenue generation in FY26 following FDA clearance.

• EMEA: aim to expand market share by signing at least four major accounts.

• Australia: retain and grow customer base, prepare for procurement opportunities.

• Ongoing investment in product optimization and next-generation automated solutions.

• No specific guidance on timing for operating cash flow break-even, but disciplined cost management and sales growth remain priorities.